Pear Therapeutics, Inc., the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), announced a manuscript accepted for publication and available via pre-print of a real-world study displaying reduced resource application and associated costs for reSET®, the only FDA-authorized PDT for the treatment of substance use disorder (SUD), including alcohol, cannabis, cocaine, and stimulants.
Results from a real-world study of reSET exhibited a statistically significant reduction in overall hospital encounters and an estimated $3,591 reduction in per-patient costs in the six months after reSET initiation compared to a 6-month pre-reSET baseline.
Read more here
More on: Health Healthcare Medical Translation News Regulatory